Galapagos is continuing to evolve under the leadership of Paul Stoffels, with the Belgium-headquartered biotech building towards its goal of bringing a ‘point-of-care’ CAR-T therapy to patients worldwide.
Galapagos Sees Global Market For Point-Of-Care CAR-T But Is Still On M&A Trail
CEO Hires Ex J&J Colleague To Continue Company Reinvention
Paul Stoffels is continuing his transformation of Galapagos into a company with CAR-T and small molecule platforms and is aiming to seal more M&A deals before the end of this year.
More from Anticancer
• By
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
• By
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
More from Therapy Areas
• By
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
• By
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.